Literature DB >> 1540976

The CySF-L2 factor from dialysable human leucocyte extract activates natural killer cytotoxicity by induction of interferon gamma.

I Doelker1, F A Anderer.   

Abstract

The mechanism of natural killer (NK) cytotoxicity activation of human peripheral blood mononuclear cells (PBMC) by CySF-L2 was elucidated. CySF-L2 is a cytotoxicity-stimulating factor isolated from dialysable human leucocyte extract, which activates NK cytotoxicity against NK-sensitive and insensitive tumour cells (K562; Daudi; Raji; MOLT4) when preincubated with effector cells for 72 h. CySF-L2-mediated activation was synergistic to interleukin-2(IL-2)-mediated activation of NK cytotoxicity. Induction of interferon gamma (IFN gamma) release was the crucial step during CySF-L2-mediated NK cytotoxicity activation since enhancement of NK activity was completely blocked when anti-IFN gamma antibodies were present during treatment of PBMC. Anti-IFN alpha, anti-TNF alpha (tumour necrosis factor alpha) anti-IL-1 and anti-IL-2 antibodies showed no blocking effect. Analysis of the supernatant culture medium after 72 h incubation of PBMC and their highly purified subpopulations demonstrated that CySF-L2 induced release of IFN gamma from CD3+T cells and CD56+CD3- NK cells and of TNF alpha and prostaglandin E2 from monocytes. CySF-L2 was also capable of activating NK cytotoxicity of highly purified (98%) CD56+CD3- NK cells as well as of monocytes (94% pure). Cell cooperation studies connected with analysis of cytokine release and enhancement of NK cytotoxicity indicated that CySF-L2 might play an essential role in the up and down regulation of NK cytotoxicity by the cytokine network.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540976     DOI: 10.1007/bf01741550

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

1.  High gradient magnetic cell separation with MACS.

Authors:  S Miltenyi; W Müller; W Weichel; A Radbruch
Journal:  Cytometry       Date:  1990

2.  Effectors, repertoire and receptors involved in lymphocyte-mediated mhc-unrestricted cytotoxicity.

Authors:  L L Lanier; J H Phillips
Journal:  Ann Inst Pasteur Immunol       Date:  1988 Jul-Aug

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  An enzyme-release assay for natural cytotoxicity.

Authors:  C Korzeniewski; D M Callewaert
Journal:  J Immunol Methods       Date:  1983-11-25       Impact factor: 2.303

5.  Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets.

Authors:  T Timonen; E Saksela; A Ranki; P Häyry
Journal:  Cell Immunol       Date:  1979-11       Impact factor: 4.868

6.  Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.

Authors:  G A Limb; A Meager; J Woolley; M Wadhwa; J Biggerstaff; K A Brown; R A Wolstencroft
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

7.  Interleukin 1- and tumor necrosis factor-stimulation of prostaglandin E2 synthesis in MDCK cells, and potentiation of this effect by cycloheximide.

Authors:  J D Leighton; J Pfeilschifter
Journal:  FEBS Lett       Date:  1990-01-01       Impact factor: 4.124

8.  Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor.

Authors:  R Munker; J Gasson; M Ogawa; H P Koeffler
Journal:  Nature       Date:  1986 Sep 4-10       Impact factor: 49.962

9.  Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon.

Authors:  S Einhorn; H Blomgren; H Strander
Journal:  Int J Cancer       Date:  1978-10-15       Impact factor: 7.396

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.